Advances in biological prognostic indicators of chronic lymphocytic leukemia

( views:, downloads: )
Author:
MA Lan(Department of Hematology,Third Hospital,Peking University,Beijing 100191,China)
WANG Jing(Department of Hematology,Third Hospital,Peking University,Beijing 100191,China)
KE Xiao-yan(Department of Hematology,Third Hospital,Peking University,Beijing 100191,China)
Journal Title:
JOURNAL OF LEUKEMIA & LYMPHOMA
Issue:
Volume 19, Issue 01, 2010
DOI:
10.3760/cma.j.issn.1009-9921.2010.01.023
Key Word:
Leukemia,lymphocytic;Prognosis;Biology

Abstract´╝Ü The patients of chronic lymphocytic leukemia(CLL)have great individual differences.It is important for clinicians to determine the prognosis at the beginning of diagnosis and choose proper treatment for the patients.The recent advances in biological prognostic indicators of CLL were reviewed,including IgVH gene mutation status,ZAP70,CD_(38),chromosome abnormality[t(11q;v),del(11q),del(17p),+12 and del(13q)].telomere and telomerase.

  • [1]Hamblin TJ,Davis Z,Gardiner A,et al.Unmutated IgV(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.Blood,1999,94:1848-1854.
  • [2]Damle RN,Wasil T,Fais F,et al.Ig VH gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytie leukemia.Blood,1999,94:1840-1847.
  • [3]Shanafelt TD,Geyer SM,Kay NE.Prognosis at diagnosis:integrating molecular biologic insights into clinical practice for patients with chronic lymphcytic leukemia.Blood,2004,103:1202-1210.
  • [4]Kharfan-Dabaja MA,Chavez JC,Khorfan KA,et al.Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia.Cancer,2008,113:897-906.
  • [5]Chen L,Widhopf G,Huynh L,et al.Expression of ZAP 70 is associated with increased B-cell receptor signaling in chronic lymphocytie leukemia.Blood,2002,100:4609-4914.
  • [6]Lin KI,Tam CS,Keating MJ,et al.Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytie leukemia treated with fludarabine,cyclophosphamide,and rituximab (FCR) or related chemoimmunotherapy regimens.Blood,2009,113:3168-3171.
  • [7]Rosenwald A,Alizadeh AA,Widhopf G,et al.Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytie leukemia.J Exp Med,2001,194:1639-1647.
  • [8]Rassenti LZ,Huynh L,Tay TL,et al.ZAP 70 compared with immunoglohulin heavy chain gene mutation status as a predictor of disease progression in chronic lymphocytie leukemia.N Engl J Med,2004,351:893-901.
  • [9]Crespo M,Bosch F,Villamor N,et al.ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytie leukemia.N Engl J Med,2003,348:1764-1775.
  • [10]Tobin G,Soderberg O,Thunberg U,et al.V (H)3-21 gene usage in chronic lymphocytie leukemia-characterization of a new subgroup with distinct molecular features and poor survival.Leuk Lymphoma,2004,45:221-228.
  • [11]Gentile M,Mauro FR,Calabrese E,et al.The prognostic value of CD_(38) expression in chronic lymphocytie leukemia patients studied prospectively at diagnosis:a single institute exprience.Br J Haematol,2005,130:549-557.
  • [12]Patten PE,Buggins AG,Richards J,et al.CD_(38) expression in chronic lymphocytie leukemia is regulated by the tumor microenvironment.Blood,2008,111:5173-5181.
  • [13]Jackson DE,Gully I.M,Henshall TL,et al.Platelet endothelial cell adhesion molecule-1 (PECAM-I/CD_(31)) is associated with a na(i)ve B-cell phenotype in human tonsils.Tissue Antigens,2000,56:105-116.
  • [14]Hamblin TJ,Orchard JA,Gardiner A,et al.Immunoglobulin V genes and CD_(38) expression in CLL.Blood,2000,95:2455-2457.
  • [15]Del Diudice I,Morilla A,Osuji N,et al.Zeta-chain associated protein 70 and CD_(38) combined predict the time to first treatment in patients with chronic lymphocytie leukemia.Cancer,2005,104:2124-2132.
  • [16]Dohner H,Stilgenbauer S,et al.Genomic aberrations and survival in chronic lymphocytie leukemia.N Engl J Med,2000,343:1910-1916.
  • [17]Hus I,Podhorecka M,Bojarska-Junak A,et al.The clinical significance of ZAP-70 and CD_(38) expression in B-cell chronic lymphocytie leukaemia.Ann Oncol,2006,17:683-690.
  • [18]Rassenti LZ,Jain S,Keating MJ,et al.Relative value of ZAP-70,CD_(38),and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytie leukemia.Blood,2008,112:1923-1930.
  • [19]Dewald GW,Brockman SR,Paternoster SF,et al.Chromosome anomalies detected by interphase fluorescence in situ hybridization:correlation with significant biological features of B-cell chronic lymphocytie leukemia.Br J Haematol,2003,121:287-295.
  • [20]Calin GA,Dumitru CD,Shimizu M,et al.Frequent deletions and downregulation of micro-RNA genes miR15 and miR16 at 13ql4 in chronic lymphocytie leukaemia.Proc Natl Acad Sci USA,2002,99:15524-15529.
  • [21]Cuneo A,Rigolin CM,Bigoni R,et al.Chronic lymphocytie leukemia with 6q-shows distinct hematological features and intermediate prognosis.Leukemia,2004,18:476-483.
  • [22]Shackelford RE,Bhalodia AR,Cotelingam JD,et al.Increased transferring receptor expression following 11q23 deletion as a mechanism of malignant progression in chronic lymphocytic leukemia.Med Hypotheses,2006,66:509-512.
  • [23]Tsimberidou AM,Keating MJ.Treatment of fludarabine-refractory chronic lymphocytic leukemia.Cancer,2009,115(13):2824-2836.
  • [24]Zenz T,H(a)be S,Denzel T,et al.Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL):dissecting the contribution of 17p deletion,TP53 mutation,p53-p21 dysfunction,and miR34a in a prospective clinical trial.Blood,2009,114:2589-2597.
  • [25]Tarn CS,Shanafelt TD,Wierda WG,et al.De novo deletion 17pl3.1 chronic lymphocytic leukemia shows significant clinical heterogeneity:the M D Anderson and Mayo Clinic experience.Blood,2009,114:957-964.
  • [26]Butler MG,Sciadini M,Hedges LK,et al.Chromosome telomere integrity of human solid neoplasms.Cancer Genet Cytogenet,1996,86:50-53.
  • [27]Damle RN,Battiwalla FM,Ghiotto F,et al.Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations.Blood,2004,103:375-382.
  • [28]Ladetto M,Compagno M,Ricca I,et al.Telomere length correlates with histopathogenesis according to the germinal center in mature B-cell lymphoproliferative disorders.Blood,2004,103:4644-4649.
  • [29]Bechter 0E,Eisterer W,Pall G,et al.Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia.Cancer Res,1998,58:4918-4922.
  • [30]Becher 0E,Eisterer W,Dlaska M,et al.CpG island methylation of the hTERT promoter is associated with lower telomerase activity in B-cell lymphocytic leukemia.Exp Hematol,2002,30:26-33.
  • [31]Terrin L,Trentin L,Degan M,et al.Telomerase expression in Bcell chronic lymphocytic leukaemia predicts survival and delineates subgroups of patients with the same IgVH mutation status and different outcome.Leukemia,2007,21:965-972.
  • [32]Verstovsek S,Giles FJ,O'Brien S,et al.Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia.Leuk Res,2004,28:707-711.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn